Retatrutide, a groundbreaking dual-acting glucose-dependent incretin mimetic, represents a significant progression in peptide therapeutics for the treatment of type 2 diabetes and, increasingly, obesity. Unlike many existing treatment interventions, retatrutide combines the actions of a GLP-1 receptor agonist and a GIP receptor agonist, offering a